Product Name: IL-33 Antibody
Species Reactivity: Human
Tested Applications: ELISA, IF, WB
Applications: IL-33 antibody can be used for the detection of IL-33 by Western blot at 1 – 2 μg/mL. Despite its predicted molecular weight, IL-33 will often run at higher molecular weight in SDS-PAGE. Antibody can also be used for immunocytochemistry starting at 20 μg/mL. For immunofluorescence start at 20 μg/mL.
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight:
Immunogen: IL-33 antibody was raised against a 19 amino acid synthetic peptide from near the amino terminus of human IL-33.The immunogen is located within amino acids 50 – 100 of IL-33.
Host Species: Rabbit
Purification: IL-33 Antibody is affinity chromatography purified via peptide column.
Physical State: Liquid
CAS NO.: 36589-58-9
Product: Ceftizoxime (sodium)
Buffer: IL-33 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration: 1 mg/mL
Storage Conditions: IL-33 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: IL-33 Antibody: DVS27, IL1F11, NF-HEV, NFEHEV, C9orf26, NFHEV, Interleukin-33, Interleukin-1 family member 11, IL-33
Accession NO.: NP_254274
Protein Ino: 15559209
Official Symbol: IL33
Geneid: 90865
Background: IL-33 Antibody: Interleukin-33 (IL-33) is a recently identified member of the IL-1 family of cytokines whose other members include IL-1α/beta, IL-1Ra and IL-18. Its receptor has been shown to be ST2, an IL-1 receptor family member that also acts as a negative regulator of TLR-IL-1R signaling and IL-1R accessory protein (IL-1RAcP). Receptor binding of IL-33 activates NF-κB and MAP kinases and induces the expression of TH2-associated cytokines such as IL-4, IL-5 and IL-6. Prolonged IL-33 treatment of mice led to the development of eosinophilia, splenomegaly, and severe pathological changes in mucosal organs such as lungs, esophagus and small intestine. Recent experiments have shown that IL-33 can also co-localize with heterochromatin and possesses transcriptional repressor activities, indicating that IL-33 may function as both a proinflammatory cytokine and an intracellular nuclear factor with transcriptional regulatory properties.
PubMed ID:http://aac.asm.org/content/26/3/426.abstract
